135733-31-2

Upstream product

• 135733-30-1 3-(hydroxymethyl)-4-phenylfuroxan 
• 104-54-1 3-Phenylpropenol 
• 4407-36-7 (2E)-3-phenyl-2-propen-1-ol 

Downstream Products

• 125520-61-8 3-phenyl-4-furoxancarboxylic acid 
• 135733-35-6 3-phenyl-4-furoxancarbaldehyde 
• 135733-30-1 3-(hydroxymethyl)-4-phenylfuroxan 
• 3672-49-9 phenyl(5-phenyl-1,2-oxazol-3-yl)methanone 
• 86340-05-8 3-benzoyl-5-phenylisoxazole oxime 
• 125520-55-0 3-carboxy-4-phenyl-1,2,5-oxadiazole 2-oxide 
• 118898-87-6 2-phenyl-2-hydroxyiminoacetonitrile oxide 
• 1380783-59-4 4-bromo-methyl-3-phenylfuroxan 
• 1380783-62-9 4-(3-phenylfuroxan-4-yl-methoxy)benzenesulfonamide 
• 1380783-74-3 C₁₅H₁₂N₂O₃ 
• 1380783-68-5 C₂₀H₂₂N₄O₆S 

Relevant academic research and scientific papers

Synthesis of Furoxans (1,2,5-oxadiazole 2-oxides) from Styrenes and Nitrosonium Tetrafluoroborate in Non-Acidic Media and Mechanistic Study

Diverse furoxans (1,2,5-oxadiazole 2-oxides) were synthesized from the corresponding styrenes using nitrosonium tetrafluoroborate as the nitrosation reagent in pyridine (basic media) or dichloromethane (neutral media). Acid-sensitive functional groups were tolerated under these conditions. The probable reaction mechanism was elucidated. The experimental results support an ionic reaction pathway in contrast to the conventional acidic conditions with a radical mechanism.

Synthesis of furoxans from styrenes under basic or neutral conditions

Furoxans (1,2,5-oxadiazole 2-oxides) can be synthesized from the corresponding styrenes using NOBF4 under basic or even almost neutral reaction conditions. Acid-sensitive functional groups are tolerated under the developed basic conditions. For

Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents

The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity.

Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis

Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents. 2009 American Chemical Society.

Pharmacochemistry of the furoxan ring: Recent developments

In the present work recent results obtained in the pharmacochemistry of the furoxan system are reported. In particular, after a brief description of the salient points of the furoxan chemistry, the synthesis and the properties of a series of Nifedipine and Prazosin analogues, containing this heterocyclic system, are described. Since we observed that a few furoxan derivatives are able to elicit both a dose-dependent rise in platelet cGMP levels and to promote a dose-dependent inhibition of AA-induced [Ca++] rise, and that many substituted furoxans show potent vasodilating and antiaggregatory activity, the possibility of using the furoxan system as a lead in the design of new vasodilators is also discussed.

Unsymmetrically Substituted Furoxans, XIII. Phenylfuroxancarbaldehydes and Related Compounds

The synthesis and structure of two isomeric phenylfuroxancarbaldehydes 7a and 7b, of the phenylfurazancarbaldehyde 6 and of the corresponding alcohols 3a, 3b and 5 are reported.Thermal equilibration of the furoxan derivatives and their oxidation to the co